Peptide derivative, and pharmaceutically acceptable salt...

Details Peptide derivative, and pharmaceutically acceptable salt... Peptide derivative, and pharmaceutically acceptable salt...

2006-06-27

2006-06-27

Campell, Bruce R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000

Reexamination Certificate

active

07067476

ABSTRACT:
The present invention provides a peptide derivative of formula (I) or a pharmaceutically acceptable salt thereofwherein X is —CH(OH)— or —CO—; R1is hydrogen or an amino protecting group; R2is hydroxyl or lower alkoxy; one of R3and R4is the side chain (R group) of lysine the amino group of which may be protected with a protecting group and the other of R3and R4is the side chain (R group) of arginine the guanidino group of which may be protected with a protecting group; and R5and R6may be the same or different and are hydrogen, lower alkyl or aralkyl. The present invention further provides a production process and use thereof.

REFERENCES:
patent: 5-97708 (1993-04-01), None
patent: 11-139947 (1999-05-01), None
patent: 11-228526 (1999-08-01), None
patent: 11-335274 (1999-12-01), None
patent: 2000-191487 (2000-07-01), None
patent: WO 02/36551 (2002-05-01), None
Kadowaki, Tomoko et al; “Suppression of Virulence ofPorphyromonas gingivalisby Potent Inhibitors Specific for Gingipains”; Current Protein and Peptide Science, vol. 4, No. 6 (2003) pp 451-458.
Gusman, Heloisa et al; “Salivary Histatin 5 Is Inhibitor of Both Host and Bacterial Enzymes Implicated in Periodontal Disease”; Infection and Immunity; Mar. 2001, pp 1402-1408.
European Search Report dated May 2, 2005.
Baba et al “New perspective of periodental disease research”; Tissue Culture Eng., 27 (9): pp343-347, 2001 (partial English Translation).
Pike et al “Lysine-and Arginine-specific Proteinases fromPorphyromonas gingivalis”;J. of Biological Chem. vol. 269 No. 1 (Jan. 7, 1994) pp406-411.
Shah et al; Biology of the SpeciesPorphyromonas gingivalis;CRC Press, Inc. 1993; pp227-243.
Dzink et al “The predominant cultivable microbiota of active and inactive lesions of destructive periodontal disease” J. Clin. Periodontol 1988: 15 pp316-323.
Slots et al “Bacteroides gingivalis, bacteroides intermediusandactinobacillus actinomycetemcomitansin human periodontal diseases” J. Clin. Periodontal 1988; 15: pp85-93.
Genco et al Host Responses in Periodontal Diseases: J. Dent. Res 63(3) Mar. 1984; pp 441-451.
International Search Report dated Dec. 24, 2002.
R. Pike, et al.; Lysine-and Arginine-specific Proteinases fromPorphyromonas gingivalis.; J. Biol. Chem.;vol. 269; No. 1; pp. 406-411./Cited in the International Search Report.
T. Baba, et al; “Tokushu Protease to Shikkan, Shishubyo Kenkyu no Saizensen—Shishu Byogen Saikin to Shishu Byogensei Inshi wa Dokomade Akirakani saretaka”;The Tissue Culture Engineering;vol. 27; No. 9; Aug. 2001; pp. 343-347./Cited in the International Search Report.

Affiliated with

Also associated with

Rating

Peptide derivative, and pharmaceutically acceptable salt... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide derivative, and pharmaceutically acceptable salt..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide derivative, and pharmaceutically acceptable salt... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3677911